Abstract

Cytokine storm syndrome is a cascade of escalated immune responses disposing the immune system to exhaustion, which might ultimately result in organ failure and fatal respiratory distress. Infection with severe acute respiratory syndrome-coronavirus-2 can result in uncontrolled production of cytokines and eventually the development of cytokine storm syndrome. Mast cells may react to viruses in collaboration with other cells and lung autopsy findings from patients that died from the coronavirus disease that emerged in 2019 (COVID-19) showed accumulation of mast cells in the lungs that was thought to be the cause of pulmonary edema, inflammation, and thrombosis. In this review, we present evidence that a cytokine response by mast cells may initiate inappropriate antiviral immune responses and cause the development of cytokine storm syndrome. We also explore the potential of mast cell activators as adjuvants for COVID-19 vaccines and discuss the medications that target the functions of mast cells and could be of value in the treatment of COVID-19. Recognition of the cytokine storm is crucial for proper treatment of patients and preventing the release of mast cell mediators, as impeding the impacts imposed by these mediators could reduce the severity of COVID-19.

Highlights

  • A Functional Role of Mast CellsBahareh Hafezi 1,† , Lily Chan 2,† , Jason P

  • Evidence has shown a potential association of Mast Cell (MC) with COVID-19, and the activation of MCs located in the submucosa of the respiratory tract by SARS-CoV-2 is known to lead to the release of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α

  • SARS-CoV-2 can cause the uncontrolled production of cytokines and the development of cytokine storm syndrome

Read more

Summary

A Functional Role of Mast Cells

Bahareh Hafezi 1,† , Lily Chan 2,† , Jason P. Knapp 2,† , Negar Karimi 1,† , Kimia Alizadeh 3,† , Yeganeh Mehrani 2,† , Byram W. Bridle 2, *,‡ and Khalil Karimi 2, *,‡. These first authors contributed to this work. These senior authors contributed to this work

Cytokine Storm Syndrome Occurs during Viral Infection and Inflammation
MC Activators May Enhance COVID-19 Vaccine-Induced Immunity
Interleukin-18
COVID-19 Drug Therapies
TNF-α-Specific Antibodies
IL-1-Specific Antibodies
IL-6-Specific Antibodies
Tocilizumab
Siltuximab
Sarilumab
Sirukumab
Baricitinib
Ruxolitinib
Targeting MCs
MC Stabilizers
Inhibitors of MC Mediators
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call